At first glance, the drugs seem like an easy solution to obesity, which continues to rise in America
The remaining specifics will be ironed out in the days following the gathering
Tomemos, por ejemplo, a un paciente hipottico, John, un hombre de 55 aos recientemente diagnosticado con diabetes tipo 2
"Our findings suggest that GLP1s may have beneficial effects on asthma control for people with obesity and this should be explored further." Prof Alan Kaplan, chairperson of the Family Physician Airways Group of Canada and the Observational and Pragmatic Research Institute, said: "Our findings suggest that GLP1-RAs have benefits on asthma control in people with obesity, and this information should contribute to the discussions around the decision to use these drugs." Dr Erika Kennington, head of research and innovation at Asthma and Lung UK, said: "Research has previously shown that people living with obesity who lose weight see improved control of their asthma, so it's encouraging to see this study show this is still the case when the weight loss is driven by drugs, like the new class of weight loss drugs
Theres no set timeline
Russald Medical Center is not affiliated with or endorsed by Novo Nordisk.) Is semaglutide for weight loss or type 2 diabetes
